Abstract
Fucosyllactoses (2'- or 3'-FL) account for up to 20% of human milk oligosaccharides (HMOs). Infant bifidobacteria, such as Bifidobacterium longum subsp. infantis, utilize the lactose moiety to form lactate and acetate, and metabolize L-fucose to 1,2-propanediol (1,2-PD). Eubacterium hallii is a common member of the adult gut microbiota that can produce butyrate from lactate and acetate, and convert 1,2-PD to propionate. Recently, a Swiss cohort study identified E. hallii as one of the first butyrate producers in the infant gut. However, the global prevalence of E. hallii and its role in utilization of HMO degradation intermediates remains unexplored. Fecal 16S rRNA gene libraries (n = 857) of humans of all age groups from Venezuela, Malawi, Switzerland, and the USA were screened for the occurrence of E. hallii. Single and co-culture experiments of B. longum subsp. infantis and E. hallii were conducted in modified YCFA containing acetate and glucose, L-fucose, or FL. Bifidobacterium spp. (n = 56) of different origin were screened for the ability to metabolize L-fucose. Relative abundance of E. hallii was low (10⁻⁵-10⁻³%) during the first months but increased and reached adult levels (0.01-10%) at 5-10 years of age in all four populations. In single culture, B. longum subsp. infantis grew in the presence of all three carbohydrates while E. hallii was metabolically active only with glucose. In co-culture E. hallii also grew with L-fucose or FL. In co-cultures grown with glucose, acetate, and glucose were consumed and nearly equimolar proportions of formate and butyrate were formed. B. longum subsp. infantis used L-fucose and produced 1,2-PD, acetate and formate in a ratio of 1:1:1, while 1,2-PD was used by E. hallii to form propionate. E. hallii consumed acetate, lactate and 1,2-PD released by B. longum subsp. infantis from FL, and produced butyrate, propionate, and formate. Beside B. longum subsp. infantis, Bifidobacterium breve, and a strain of B. longum subsp. suis were able to utilize L-fucose. This study identified a trophic interaction of infant bifidobacteria and E. hallii during L-fucose degradation, and pointed at E. hallii as a metabolically versatile species that occurs in infants and utilizes intermediates of bifidobacterial HMO fermentation.
Introduction
The infant gut microbiome is a dynamic ecosystem where early colonizers set the stage for long-term health. Human milk oligosaccharides (HMOs), such as 2'- or 3'-fucosyllactose (FL), are critical prebiotics that support the growth of beneficial Bifidobacterium species. However, the production of other essential metabolites like butyrate—a short-chain fatty acid (SCFA) vital for gut barrier function—remains poorly understood in the fiber-free diet of infants. This study investigates the trophic interactions between Bifidobacterium longum subsp. infantis and Eubacterium hallii, revealing how they collaborate to produce health-promoting SCFAs from HMO degradation products.
Global Prevalence of E. hallii
To understand the ecological niche of E. hallii, researchers analyzed fecal 16S rRNA gene libraries from 857 individuals across Venezuela, Malawi, Switzerland, and the USA. The data revealed a consistent global pattern: E. hallii is present at very low levels (10⁻⁵% to 10⁻³%) during early infancy but steadily increases, reaching adult levels (0.01% to 10%) between 5 and 10 years of age. This suggests that while E. hallii is a common adult gut microbe, it establishes itself early in life, likely supported by the metabolic activities of other infant-associated bacteria.
Metabolic Synergy in the Infant Gut
The study utilized in vitro co-cultures to map the metabolic pathways between B. infantis and E. hallii. While B. infantis is a specialist capable of degrading complex HMOs like FL, E. hallii acts as a metabolic generalist, scavenging the breakdown products.
When grown on L-fucose or FL, B. infantis produces intermediates including acetate, formate, and 1,2-propanediol (1,2-PD). In co-culture, E. hallii utilizes these intermediates—specifically consuming 1,2-PD to produce propionate and utilizing lactate and acetate to produce butyrate. This "Bifid shunt" bypasses the need for dietary fiber, explaining how butyrate can be produced in the infant gut long before the introduction of solid foods.
Conclusion
The discovery that Bifidobacterium breve and certain B. longum strains also possess the machinery for fucose utilization suggests this trophic interaction may be widespread. However, maternal factors, such as "non-secretor" status (lacking fucose in HMOs), could potentially disrupt this beneficial metabolic chain. This study highlights the importance of microbial teamwork in the developing gut, identifying E. hallii as a versatile partner that bridges the gap between infant milk-based diets and adult fiber-based metabolism.
Summary updated